Treatments

Latest News

Relapse-Free Cure From MDR-TB Higher Than Anticipated

Relapse-Free Cure From MDR-TB Higher Than Anticipated

The frequency of relapse-free cure from multidrug-resistant tuberculosis is higher than previously anticipated.

Similar Safety and Efficacy for Rifampin vs Isoniazid in Children, Adolescents

Similar Safety and Efficacy for Rifampin vs Isoniazid in Children, Adolescents

For children younger than 18 years, 4 months of rifampin to treat latent Mycobacterium tuberculosis had similar rates of safety and efficacy and higher rates of adherence compared with 9 months of isoniazid.

AHA Issues Scientific Statement on Managing Chagas Cardiomyopathy

AHA Issues Scientific Statement on Managing Chagas Cardiomyopathy

The most common findings in patients with Chagas cardiomyopathy include cardiac rhythm abnormalities, myocardial abnormalities, aneurysms, and thromboembolism.

Is Short-Course Antibiotic Treatment for CAP Effective?

Is Short-Course Antibiotic Treatment for CAP Effective?

To investigate what impact antibiotic treatment duration has on CAP outcomes, researchers from the Warren Alpert Medical School of Brown University conducted a search of various databases for studies comparing the safety and efficacy of treatment regimens lasting ≤6 days (short) and ≥7 days (long).

FDA Strengthens Warnings for Fluoroquinolone Antibiotics

FDA Strengthens Warnings for Fluoroquinolone Antibiotics

The labeling changes are based on a review of postmarketing adverse event reports found in the FDA Adverse Event Reporting System (FAERS) database and published medical literature.

FDA Approves Plazomicin for Complicated Urinary Tract Infections

FDA Approves Plazomicin for Complicated Urinary Tract Infections

Zemdri carries a Boxed Warning describing reports of nephrotoxicity, ototoxicity, and neuromuscular blockade, as well as fetal harm if administered during pregnancy.

Potential Significant Toxicity With Methotrexate, Trimethoprim-Sulfamethoxazole Combination

Potential Significant Toxicity With Methotrexate, Trimethoprim-Sulfamethoxazole Combination

The case involved a 68-year-old female patient with rheumatoid arthritis on methotrexate 10mg weekly who presented to the emergency department with complaints of lethargy and weakness after being prescribed a 2-week course of TS for a bacterial skin infection.

FDA Approves New Treatment for Onchocerciasis

FDA Approves New Treatment for Onchocerciasis

Moxidectin, a macrocyclic lactone, is an anthelmintic drug that selectively binds to the parasite's glutamate-gated chloride ion channels.

FDA Grant Orphan Drug Status to Brincidofovir for Smallpox

FDA Grant Orphan Drug Status to Brincidofovir for Smallpox

Brincidofovir is the Company's lead candidate, a nucleotide analog that has antiviral activity against variola virus, which causes smallpox.

Treatment for Prosthetic Joint Infections Gets FDA's QIDP Designation

Treatment for Prosthetic Joint Infections Gets FDA's QIDP Designation

PJI is a challenging complication of joint arthroplasty with few effective treatment options.

Sign Up for Free e-newsletters